Status:
RECRUITING
Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations
Lead Sponsor:
Centre Hospitalier Régional Metz-Thionville
Collaborating Sponsors:
University of Lorraine
Conditions:
Magnetic Resonance Imaging
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate i...
Detailed Description
The contrast agents used in MRI to characterize certain lesions contain a chemical element from the rare earth family: Gadolinium (Gd). Gd, in its isolated form, is toxic in humans, but it can still b...
Eligibility Criteria
Inclusion
- Patients:
- over 18 years of age
- with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist
- affiliated with a health insurance plan
- have signed an informed consent form
Exclusion
- Patients:
- with known allergy to gadolinium-based contrast agents (Gd-CAs)
- with known severe renal impairment (GFR \< 30 mL/min)
- on dialysis
- with urinary incontinence
- with an ongoing urinary tract infection
- under hydric or hydrosodic restriction
- unable to urinate independently
- Protected persons (under guardianship, curatorship or safeguard of justice)
- Pregnant or breast-feeding women
Key Trial Info
Start Date :
April 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 12 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06191731
Start Date
April 12 2024
End Date
April 12 2026
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHR Metz-Thionville/Hopital de Mercy
Metz, Grand Est, France